97 related articles for article (PubMed ID: 17092665)
1. Why is the RUTH trial so important?
Pines A; Levo Y
Maturitas; 2007 Feb; 56(2):111-2. PubMed ID: 17092665
[No Abstract] [Full Text] [Related]
2. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
3. Baseline characteristics of menopausal women with coronary heart disease in cardiovascular outcomes clinical trials of menopausal hormone therapy or raloxifene.
Wenger NK; Geiger MJ
Contemp Clin Trials; 2005 Dec; 26(6):612-5. PubMed ID: 16257585
[TBL] [Abstract][Full Text] [Related]
4. Ovarian failure including menopause, premature menopause, and resistant ovarian syndrome, and hormonal replacement.
Katz E; McClamrock HD; Adashi EY
Curr Opin Obstet Gynecol; 1990 Jun; 2(3):392-7. PubMed ID: 2102334
[No Abstract] [Full Text] [Related]
5. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
Rosa J; Vanuga P; Payer J; Svobodník A
Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
[TBL] [Abstract][Full Text] [Related]
6. Drug information needs clarification.
Grossman LD
Can Fam Physician; 2001 Jan; 47():28-30. PubMed ID: 11212427
[No Abstract] [Full Text] [Related]
7. Raloxifene and risk for stroke based on the framingham stroke risk score.
Barrett-Connor E; Cox DA; Song J; Mitlak B; Mosca L; Grady D
Am J Med; 2009 Aug; 122(8):754-61. PubMed ID: 19540454
[TBL] [Abstract][Full Text] [Related]
8. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
9. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
Ohta H
Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
[TBL] [Abstract][Full Text] [Related]
10. [Evidence of hormone replacement therapy for osteoporosis].
Tarakida A; Higuchi T; Mizunuma H
Clin Calcium; 2008 Oct; 18(10):1434-41. PubMed ID: 18830040
[TBL] [Abstract][Full Text] [Related]
11. Estrogen and the prevention and treatment of osteoporosis.
Battistini M
Rev Rhum Engl Ed; 1997 Jun; 64(6 Suppl):44S-49S. PubMed ID: 9273937
[No Abstract] [Full Text] [Related]
12. Effect of raloxifene on the vaginal epithelium of postmenopausal women.
Delmanto A; Nahas-Neto J; Nahas EA; de Oliveira ML; Fernandes CE; Traiman P
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):187-92. PubMed ID: 18400357
[TBL] [Abstract][Full Text] [Related]
13. Menopause and stroke and the effects of hormonal therapy.
Lobo RA
Climacteric; 2007 Oct; 10 Suppl 2():27-31. PubMed ID: 17882669
[TBL] [Abstract][Full Text] [Related]
14. [Biochemical markers of bone turnover. New aspect. Effects of androgen and estrogen on biochemical markers of bone turnover].
Ohnaka K; Takayanagi R
Clin Calcium; 2009 Aug; 19(8):1118-24. PubMed ID: 19638695
[TBL] [Abstract][Full Text] [Related]
15. [Evidence-based medicine and drug selection of osleoporosis prevention after menopause].
Xu L
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):265-6. PubMed ID: 15059503
[No Abstract] [Full Text] [Related]
16. Clarification needed for raloxifene use.
Reinders M
Can Fam Physician; 2000 Nov; 46():2185. PubMed ID: 11143573
[No Abstract] [Full Text] [Related]
17. Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.
Schaefers M; Muysers C; Alexandersen P; Christiansen C
Menopause; 2009; 16(3):559-65. PubMed ID: 19423999
[TBL] [Abstract][Full Text] [Related]
18. Skeletal pain in postmenopausal women with osteoporosis: prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration.
Scharla S; Oertel H; Helsberg K; Kessler F; Langer F; Nickelsen T
Curr Med Res Opin; 2006 Dec; 22(12):2393-402. PubMed ID: 17257453
[TBL] [Abstract][Full Text] [Related]
19. The effect of raloxifene in association with vitamin D on vaginal maturation index and urogenital symptoms in postmenopausal osteoporotic women.
Zeyneloglu HB; Oktem M; Haberal NA; Esinler I; Kuscu E
Fertil Steril; 2007 Aug; 88(2):530-2. PubMed ID: 17336964
[TBL] [Abstract][Full Text] [Related]
20. [Conventional hormonal replacement therapy in treatment of osteoporosis].
Meczekalski B; Czyzyk A
Pol Merkur Lekarski; 2009 Jul; 27(157):72-6. PubMed ID: 19650436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
